VWF, aVWF, ADAMTS-13, MPO, and TSP values during the first 10 days in the ICU
| . | VWF, μg/mL (IQR) . | aVWF, μg/mL (IQR) . | ADAMTS-13, μg/mL (IQR) . | MPO, ng/mL (IQR) . | TSP, ng/mL (IQR) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . |
| Day 1, N = 228; 47 | 46.0 (31.3-63.9) | 50.1 (29.6-80.8) | 0.47 (0.30-0.82) | 0.69 (0.35-1.68) | 0.46 (0.31-0.68) | 0.40 (0.22-0.62) | 46 (23-75) | 52 (32-93) | 515 (809-294) | 428 (266-718) |
| Day 2, N = 224; 46 | 46.7 (32.2-68.3) | 57.6 (38.0-87.8) | 0.51 (0.29-0.83) | 0.79 (0.41-1.44) | 0.49 (0.31-0.71) | 0.34 (0.20-0.62) | 37 (21-64) | 49 (21-107) | 495 (220-753) | 388 (257-699) |
| Day 3, N = 208; 38 | 51.5 (34.7-72.3) | 50.9 (37.3-109.3) | 0.50 (0.34-0.86) | 1.02 (0.55-1.25) | 0.48 (0.29-0.76) | 0.31 (0.14-0.48) | 36 (20-61) | 52 (25-100) | 573 (281-895) | 469 (199-646) |
| Day 4, N = 187; 34 | 49.9 (34.0-68.1) | 51.1 (34.7-83.7) | 0.51 (0.31-0.94) | 0.71 (0.47-1.35) | 0.44 (0.28-0.69) | 0.31 (0.18-0.53) | 33 (17-52) | 46 (24-66) | 538 (287-763) | 418 (174-718) |
| Day 5, N = 170; 31 | 50.6 (38.4-67.8) | 50.5 (38.7-81.9) | 0.56 (0.36-0.97) | 0.76 (0.36-1.19) | 0.43 (0.24-0.72) | 0.28 (0.19-0.26) | 29 (18-51) | 28 (17-62) | 545 (251-841) | 372 (190-780) |
| Day 6, N = 155; 28 | 51.1 (36.3-67.8) | 60.6 (41.3-102.4) | 0.59 (0.36-1.03) | 0.62 (0.41-1.02) | 0.38 (0.25-0.68) | 0.29 (0.17-0.49) | 27 (14-46) | 35 (19-66) | 522 (258-799) | 381 (196-626) |
| Day 7, N = 141; 23 | 51.7 (37.5-74.0) | 56.2 (35.5-121.2) | 0.55 (0.35-1.23) | 0.58 (0.44-1.09) | 0.36 (0.24-0.64) | 0.28 (0.19-0.50) | 26 (17-43) | 43 (23-61) | 531 (289-867) | 342 (157-517) |
| Day 8, N = 127; 16 | 51.8 (37.1-73.3) | 58.3 (38.4-120.1) | 0.65 (0.33-1.00) | 0.62 (0.43-1.21) | 0.38 (0.24-0.59) | 0.29 (0.15-0.65) | 24 (14-44) | 41 (30-72) | 463 (234-717) | 396 (244-658) |
| Day 9, N = 107; 12 | 53.0 (36.5-79.0) | 58.8 (47.0-88.7) | 0.56 (0.38-1.16) | 0.58 (0.45-0.85) | 0.40 (0.19-0.69) | 0.22 (0.14-0.38) | 24 (14-48) | 60 (40-75) | 441 (259-697) | 598 (361-783) |
| Day, 10 N = 85; 5 | 51.1 (36.7-72.7) | 45.0 (43.5-93.4) | 0.56 (0.40-0.95) | 0.59 (0.48-0.85) | 0.39 (0.24-0.70) | 0.29 (0.11-0.35) | 20 (14-46) | 66 34-68) | 478 (267-678) | 460 (281-771) |
| . | VWF, μg/mL (IQR) . | aVWF, μg/mL (IQR) . | ADAMTS-13, μg/mL (IQR) . | MPO, ng/mL (IQR) . | TSP, ng/mL (IQR) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . | Survivors . | Nonsurvivors . |
| Day 1, N = 228; 47 | 46.0 (31.3-63.9) | 50.1 (29.6-80.8) | 0.47 (0.30-0.82) | 0.69 (0.35-1.68) | 0.46 (0.31-0.68) | 0.40 (0.22-0.62) | 46 (23-75) | 52 (32-93) | 515 (809-294) | 428 (266-718) |
| Day 2, N = 224; 46 | 46.7 (32.2-68.3) | 57.6 (38.0-87.8) | 0.51 (0.29-0.83) | 0.79 (0.41-1.44) | 0.49 (0.31-0.71) | 0.34 (0.20-0.62) | 37 (21-64) | 49 (21-107) | 495 (220-753) | 388 (257-699) |
| Day 3, N = 208; 38 | 51.5 (34.7-72.3) | 50.9 (37.3-109.3) | 0.50 (0.34-0.86) | 1.02 (0.55-1.25) | 0.48 (0.29-0.76) | 0.31 (0.14-0.48) | 36 (20-61) | 52 (25-100) | 573 (281-895) | 469 (199-646) |
| Day 4, N = 187; 34 | 49.9 (34.0-68.1) | 51.1 (34.7-83.7) | 0.51 (0.31-0.94) | 0.71 (0.47-1.35) | 0.44 (0.28-0.69) | 0.31 (0.18-0.53) | 33 (17-52) | 46 (24-66) | 538 (287-763) | 418 (174-718) |
| Day 5, N = 170; 31 | 50.6 (38.4-67.8) | 50.5 (38.7-81.9) | 0.56 (0.36-0.97) | 0.76 (0.36-1.19) | 0.43 (0.24-0.72) | 0.28 (0.19-0.26) | 29 (18-51) | 28 (17-62) | 545 (251-841) | 372 (190-780) |
| Day 6, N = 155; 28 | 51.1 (36.3-67.8) | 60.6 (41.3-102.4) | 0.59 (0.36-1.03) | 0.62 (0.41-1.02) | 0.38 (0.25-0.68) | 0.29 (0.17-0.49) | 27 (14-46) | 35 (19-66) | 522 (258-799) | 381 (196-626) |
| Day 7, N = 141; 23 | 51.7 (37.5-74.0) | 56.2 (35.5-121.2) | 0.55 (0.35-1.23) | 0.58 (0.44-1.09) | 0.36 (0.24-0.64) | 0.28 (0.19-0.50) | 26 (17-43) | 43 (23-61) | 531 (289-867) | 342 (157-517) |
| Day 8, N = 127; 16 | 51.8 (37.1-73.3) | 58.3 (38.4-120.1) | 0.65 (0.33-1.00) | 0.62 (0.43-1.21) | 0.38 (0.24-0.59) | 0.29 (0.15-0.65) | 24 (14-44) | 41 (30-72) | 463 (234-717) | 396 (244-658) |
| Day 9, N = 107; 12 | 53.0 (36.5-79.0) | 58.8 (47.0-88.7) | 0.56 (0.38-1.16) | 0.58 (0.45-0.85) | 0.40 (0.19-0.69) | 0.22 (0.14-0.38) | 24 (14-48) | 60 (40-75) | 441 (259-697) | 598 (361-783) |
| Day, 10 N = 85; 5 | 51.1 (36.7-72.7) | 45.0 (43.5-93.4) | 0.56 (0.40-0.95) | 0.59 (0.48-0.85) | 0.39 (0.24-0.70) | 0.29 (0.11-0.35) | 20 (14-46) | 66 34-68) | 478 (267-678) | 460 (281-771) |
Data are presented as medians. IQR is between the 25th and 75th percentiles.
N, numbers of survivors and nonsurvivors.